Sun Min Lim

Yonsei University College of Medicine
Country flagSouth Korea

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (51)

Supplementary Figure 8. Circulating tumor DNA analysis data from Case 1. A, Allelic configuration analysis by liquid biopsy confirmed cis relationship between EGFR T790M and C797S mutations; no trans clones were detected. B, Serial changes in allelic frequency of all mutations detected in blood.

Year:

2025

(A-B) Cells were incubated with the REGN5093-M114, IgG4 control-M114, osimertinib for 5 days, capmatinib for 3 days. Cell viability was analyzed via CellTiter-Glo. The curved graphs show the cell viability results for a single drug, and the bar-graphs show the cell viability for the combination of two drugs.

Year:

2025

(A-B) Each cell viability was measured after treatment with REGN 5093-M114 for 5 days, capmatinib and tepotinib for 3 days. REGN 5093-M114 was treated with concentration of 0 µg/ml, 0.03 µg/ml, 0.1 µg/ml, 0.3 µg/ml, 1 µg/ml, 3 µg/ml. MET TKIs, capmatinib and tepotinib were treated with serial concentrations from 0nM to 100nM.

Year:

2025

Genomic landscape in patient-derived preclinical models. The genetic alteration of the PDC (patient-derived cell), PDO (patient-derived organoid), and PDX (patient-derived xenograft) models are shown as an oncoprint plot.

Year:

2025

Supplementary Figure 6. Analysis of BBT-176 using in vivo models. A, Body weight changes in Ba/F3 EGFR 19Del/C797S, EGFR 19Del/T790M/C797S and patient-derived xenograft models. The patient-derived xenograft was derived from a patient with poorly-differentiated adenocarcinoma harboring an EGFR 19Del/T790M/C797S mutation. B, BBT-176 activity in a LU1235 EGFR 19Del patient-derived xenograft model. Abbreviations: PDX, patient-derived xenograft; PO, orally; QD, once daily.

Year:

2025

Supplementary Figure 10. Growth inhibition by BBT-176 with and without osimertinib in BBT-176-resistant clones of EGFR 19Del/C797S (A) and EGFR 19Del/T790M/C797S (B) mutants. C, IC50 values for BBT-176 with and without osimertinib in BBT-176-resistant clones. IC50 values in nM were measured 3 days later and cell growth was plotted relative to untreated control cells (mean ± SD). Abbreviation: BR(1/2), BBT-176-resistant (clone 1/2).

Year:

2025

(A-D) YUO-006 and YUO-010 (Patient-derived organoids), YU-1089 and YU-1095 (Patient-derived cells) or HCC827-AR and H820 (ATCC cell lines) were seeded on a 96-well plate and incubated with the MET TKIs (tepotinib) and EGFR TKIs (osimertinib or gefitinib) for 3 days. EGFR TKIs was treated with concentration of 0nM, 30nM, 100nM. MET TKIs, tepotinib were treated with serial concentrations from 0nM to 100nM. The bar-graphs show the cell viability for the combination of two drugs, and the curved graphs show the cell viability results for a single drug.

Year:

2025

(A-B) Apoptosis level was measured after incubated with drugs for 48 hours. YU1089 and HCC827 AR cells were treated with osimertinib, capmatinib or tepotinib at a concentration of 100nM, Control Ab-M114 at 1 µg/ml or REGN5093-M114 at 1 µg/ml.

Year:

2025

Cells were seeded on a 96-well plate and incubated with the REGN5093-M114, Control Ab-M114, and EGFR TKIs (osimertinib, lazertinib). Cell viability was measured after 5 days of REGN5093-M114 treatment and 3 days of capmatinib treatment via CellTiter-Glo. The curved graphs show the cell viability results for a single drug, and the bar-graphs show the cell viability for the combination of two drugs.

Year:

2025

Supplementary Figure 9. Circulating tumor DNA analysis data from Case 2. A, Allelic configuration of T790M (red), L792H (green) and C797S (blue). B, Serial changes in allelic frequency of mutations detected in blood. C, Concentration-response curves and IC50 values of BBT-176 for EGFR 19Del/T790M/L792H mutant kinase.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (12)

Jin Seok Ahn

Professor

Samsung Medical Center

SOUTH KOREA
View details

Kyoung-Ho Pyo

Yonsei University College of Medicine

SOUTH KOREA
View details

Taiguang Jin

Head of Discovery Biology

BrightPath Biotherapeutics

UNITED STATES
View details

Mi Ran Yun

Yonsei University College of Medicine

SOUTH KOREA
View details

Gwanghee Lee

-

SOUTH KOREA
View details

Byoung Chul Cho

PI/Professor

-

SOUTH KOREA
View details

Mi Ra Yu

Research Assistant Professor

Yonsei University College of Medicine

SOUTH KOREA
View details

Seong Gu Heo

Dana-Farber Cancer Institute

UNITED STATES
View details

Christopher Daly

Regeneron Pharmaceuticals

UNITED STATES
View details

Min Hee Hong

Associate Professor

Severance Hospital

SOUTH KOREA
View details

Dong-Wan Kim

Associate Professor

Seoul National University Hospital

SOUTH KOREA
View details

Tetsuya Mitsudomi

Professor

Kindai University

JAPAN
View details